MD Anderson researchers develop novel antibody-toxin conjugate
Researchers at The University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to...
MD Anderson, the Oden Institute and TACC announce funding...
The University of Texas MD Anderson Cancer Center, the Oden Institute for Computational Engineering and Sciences and the Texas...
Funda Meric-Bernstam, M.D., elected to National Academy of...
Funda Meric-Bernstam, M.D., chair of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, has...
MD Anderson Research Highlights Special Edition: ASTRO 2024
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research...
Allison Institute and Institute for Data Science in...
The James P. Allison Institute™ and the Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer...
ESMO: Novel ADC AZD8205 demonstrates manageable safety...
ABSTRACT: 606O
BARCELONA, Spain – The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety...
MD Anderson and Rice launch initiative to advance...
The University of Texas MD Anderson Cancer Center and Rice University today announced the launch of the Center for Operations Research...
Study supports precision radiation therapy in lung cancer
Results from a new study led by researchers at The University of Texas MD Anderson Cancer Center support standard use of the more...
MD Anderson’s Institute for Data Science in Oncology...
The Institute for Data Science in Oncology (IDSO) at The University of Texas MD Anderson Cancer Center today announced the...
ASCO: Proton therapy demonstrates advantages in Phase III...
ABSTRACT 6006
According to preliminary data from a multi-institution Phase III trial led by researchers at The University of...